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ABSTRACT 
Purpose of review 
Given the worldwide shortage of Bacillus Calmette–Guérin (BCG) we review the efficacy of 
alternative BCG application schedules, doses or strains and intravesical chemotherapy in 
patients with non-muscle-invasive bladder cancer (NMIBC). 
Recent findings 
Modifying BCG schedules by reducing the dose is preferable to reducing the frequency of 
BCG which increases recurrence rates and should be avoided if possible. Changing the BCG 
substrain represents a reasonable option as current evidence does not suggest different 
oncological outcomes with specific BCG substrains. Mitomycin C (MMC) alone is inferior to 
BCG with maintenance but promising results have been demonstrated when used with 
chemohyperthermia and electromotive drug administration . Several other intravesical 
chemotherapies including Gemcitabine and Epirubicin should be used when both BCG and 
MMC are in short supply. 
Summary 
In case of BCG shortage much will depend on the severity and length of the BCG shortage 
but our review supports several solutions: First, we recommend contacting the local 
pharmacist or BCG supplier to consider alternative BCG strains or sterile splitting of BCG 
doses. In the complete absence of BCG, consideration should be given to MMC with 
chemohyperthermia or electromotive drug administration where available or other 
intravesical chemotherapy.  High-risk patients should be considered for cystectomy.  
 
Keywords: bladder cancer, Bacillus Calmette–Guérin, BCG, shortage, gemcitabine, 
intravesical therapy, mitomycin C 
INTRODUCTION 
Bladder cancer is the second most common malignancy of the urinary tract and leads to 
400’000 new diagnoses and 160,000 deaths per year worldwide with an estimated increase of 
40% by 2035 (1). Around 75% of patients with bladder cancer have non-muscle-invasive 
bladder cancer (NMIBC) for which the cornerstone of management currently is transurethral 
resection of the bladder (TURB) (2). Current guidelines recommend the use of intravesical 
Bacillus Calmette– Guérin (BCG) in patients with intermediate to high-risk NMIBC to 
reduce the risk of recurrence and progression (2, 3). It has been estimated that the global 
demand for BCG is up to 2 million doses per year but Merck (Kenilworth, NJ, USA) the 
current global market leader can only produce 700,000 doses globally. Closures of BCG 
plants in 2012 and 2014, reduction of production in 2015 and the withdrawal of a large BCG 
manufacturer in 2017 has led to sustained worldwide shortages of BCG. Given the 
methodological complexity and high demands of BCG production future shortages are to be 
expected (4). In this report, we briefly review alternative BCG application schedules, doses, 
strains and intravesical therapies and provide recommendations for periods of BCG shortage. 
METHODS 
We conducted a literature search on using the Medline database. For our literature research, 
we used combinations, synonyms and related search terms to “bladder” and “cancer” and 
“nutrition” or “lifestyle” and selected the time period between 1st of November 2017 until 
November 18th 2019. The following search terms were used: ((((("2017/11/01"[Date - 
Publication] : "3000"[Date - Publication])) AND ((( (bladder[Title/Abstract] OR 
urothel*[Title/Abstract]) AND (cancer*[Title/Abstract] OR adenocarcinoma[Title/Abstract] 
OR carcinoma*[Title/Abstract] OR malignan*[Title/Abstract] OR neoplasm*[Title/Abstract] 
OR tumor*[Title/Abstract] OR tumour*[Title/Abstract]) ) AND Bcg[Title/Abstract]))))). 
Non-English literature, animal studies, case reports and correspondence/letters were 
excluded. 
 
CHANGE OF BCG SCHEDULE 
During a period of BCG shortage the standard BCG schedule of full dose induction followed 
by up to 3 years of maintenance BCG can be adapted. Broadly there are three options 1) 
Reduce the dose of each instillation 2) Shorten the length of the BCG course 3) Reduce the 
number of instillations per maintenance cycle. 
 
1) Reducing the dose of each instillation  
Based on the results of an EORTC-GU group trial patients could be treated with a one third 
dose of BCG for induction and maintenance. This was not inferior to full dose BCG for 
progression or overall survival although it was associated with a higher recurrence rate (5). 
This approach does have logistical challenges: unlike a standard vial of full dose BCG it is 
not possible to prepare one third dose BCG using a closed system and preparation of the BCG 
will most likely need to be carried out under aseptic conditions in pharmacy.  Concerns have 
been raised about suboptimal dosing in patients but it should be pointed out that as an 
example, each vial of TICE BCG (Merck, Kenilworth NJ, USA) contains between 1-8x108 
CFU, an eightfold difference. Given this wide variation in CFUs that already exists in a 
single vial, splitting this into a third will not necessarily result in suboptimal dosing. However 
one third dose seems to be the minimum dose for clinical effectiveness as it has been shown 
that one sixth dose BCG was inferior to one third dose BCG (6). Furthermore, the split dose 
BCG cannot be stored overnight and should ideally be used within 2 hours so 3 patients will 
need to be treated at the same time which is logistically difficult although up to 8 hours is 
feasible to “share” the same vial and stagger treatment timings (personal communication, 
A.Kamat, Houston, USA).  
 
2.) Shorten the length of the BCG course   
Although a maintenance course of BCG is the current standard of care, an induction course of 
BCG alone may be considered if dose splitting is impossible and intravesical chemotherapy is 
not available. Herr et al. have shown that when an induction course of 6 BCG instillations is 
given alone, only one third of patients required a further course of BCG. However an 11% 5 
year progression rate was seen which is higher than when maintenance BCG is used (7). 
Therefore if BCG supplies allow it maintenance BCG should always be given and it is 
probably better for a patient to receive one third dose BCG induction and 12 maintenance 
instillations over 18 months, which requires a total equivalent of 6 vials, than the same 
number of vials as full dose BCG induction only.    
The EORTC-GU group have shown that reducing the length of maintenance from 3 years to 1 
year has no effect on progression or death but is associated with an increased recurrence rate 
(5). However patients with CIS should still be offered 3 years of maintenance (at a reduced 
dose of one third if necessary) (8).  
 
3.) Reducing the number of instillations per maintenance cycle  
Although this may appear to be an attractive option when compared to the difficulties 
associated with preparing a reduced dose, it has been shown that a single instillation per 
maintenance cycle for 3 years is no better than an induction course alone (6).  Furthermore 
the EAU Research Foundation recently halted the NIMBUS trial, a randomized trial studying 
the effects a reduced number of instillations following a safety analysis by the independent 
data monitoring committee showing that a reduced instillation schedule was inferior to a 
standard instillation schedule (9) 
 
CHANGE OF BCG STRAIN  
Given the genetic difference between BCG substrains several clinical trials and meta-analyses 
have studied whether substrains differ regarding oncological outcomes. However, only a 
limited number of sufficiently powered trials with head-to-head comparisons have been 
published (10). The current literature has been summarized by several meta-analyses with 
diverging results. A network meta-analysis which aimed to simulate direct comparisons 
between substrains suggested that BCG is superior compared to intravesical chemotherapy 
only but no single substrain was superior compared to the others BCG substrains (11). In 
contrast, a meta-analysis without network comparisons suggested that patients treated with 
TICE had a higher risk of recurrence compared to Connaught or RIVM (12). This currently 
limited evidence will be improved by two interesting trials. The first ongoing trial was started 
because TICE BCG became the predominant strain in the USA. As a consequence, the 
Southwest Oncology Group has launched the S1602 trial comparing TICE BCG to the Tokyo 
substrain, and tests whether subcutaneous inoculation of BCG will improve oncologic 
responses(13). The second ongoing trial is a phase I/II trial which will assess the safety and 
efficacy of recombinant BCG VPM1002BC (NCT02371447). In absence of clear evidence 
regarding superior efficacy of one specific substrain, we recommend that during BCG 
shortage Urologists should discuss with their BCG provider or pharmacist whether alternative 
BCG substrains can be provided. 
 
INTRAVESICAL CHEMOTHERAPY 
In view of the interruptions to BCG supplies over the past years, several intravesical 
chemotherapies have been studied. 
 
Mitomycin C  
Intravesical mitomycin C (MMC) is the most extensively investigated chemotherapy agent in 
patients with NMIBC. An individual patient data meta-analysis of nine randomized controlled 
trials suggested a 32% higher risk of recurrence following MMC when compared to BCG 
maintenance but conversely a 28% reduction in risk of recurrence when compared to BCG 
induction alone. It is perhaps worth emphasizing that there were no significant differences in 
disease progression, cancer-specific survival and overall survival (14). Another advantage of 
MMC compared to BCG is that is has fewer side effects (15).  
Chemohyperthermia with Mitomycin C 
A randomized study comparing radiofrequency-induced chemohyperthermia using MMC 
with BCG showed promising 24-month recurrence-free survival rates of 78% and 65% 
respectively  (p=0.08) (16). Another randomized study compared between radiofrequency-
induced chemohyperthermia using MMC (6-weekly induction instillations, followed by 
maintenance instillations at 6-week intervals for the first year and at 8-week intervals for the 
second year) and BCG (induction and maintenance for one year) in patients with recurrent 
intermediate- and high-risk NMIBC following induction and/or maintenance BCG (17). 
Overall, there were no differences in complete response at 3 months and disease-free survival 
between the two groups. However, subgroup analyses showed that patients with CIS had a 
lower disease-free survival with chemohyperthermia. The HIVEC 1&2 trials investigating the 
use of conductive chemohyperthermia are currently under way (18). 
 
Electromotive MMC and sequential BCG  
One randomized study investigated the use of electromotive MMC and sequential BCG 
induction and maintenance in patients with T1 bladder cancer (19). Patients in the sequential 
treatment group showed significantly lower recurrence (42% vs 58%), progression (9% vs 
22%, disease-specific (6% vs 16%) and overall mortality (22% vs 32%) rates than the BCG-
alone group. The sequential use of electromotive MMC and BCG can also reduce the total 
amount of BCG being used (9 doses vs 16 doses per patient), however, it is challenging due 
to logistical reasons and a relatively complicated treatment schedule.  
 
Gemcitabine 
There were two randomized trials comparing between intravesical gemcitabine and BCG in 
BCG-naïve NMIBC. In the first study by Bendary et al. (20), patients with primary Ta or T1 
disease without CIS were randomized to receive six weekly intravesical instillations of either 
gemcitabine or BCG. There were no significant differences in the recurrence and progression 
rates between the two groups. In the second study by Porena et al. (21), patients with high-
risk NMIBC were randomized to receive three years of either gemcitabine or BCG. Patients 
in the gemcitabine group had a higher recurrence rate than the BCG group (53% vs 28%). 
None of the patients developed disease progression. 
 
Epirubicin 
Two randomized trials compared epirubicin with BCG showed inferior oncological outcomes 
with epirubicin. The first trial including intermediate- and high-risk NMIBC patients who 
received up to three years of BCG had lower risks of recurrence, distant metastasis, bladder 
cancer-specific mortality and overall mortality than those who received up to three years of 
intravesical epirubicin (22). In a second trial comparing BCG with the combination of 






Other chemotherapy agents  
The use of other chemotherapy agents including doxorubicin (24), valrubicin (25), 
pirarubicin (26) and docetaxel (27) has been proposed in the literature. However, data 
regarding their efficacies and how they compare with BCG therapy are very limited. Further 
high-quality studies will be needed before these agents can be recommended. 
 
CYSTECTOMY 
High-risk NMIBC is a difficult disease to manage, and the progression rate can be up to 17% 
at one-year and 45% at 5 years (28). Moreover, in patients with T1G3 disease, the pathology 
is upstaged to muscle-invasive disease in over 50% (29, 30). In a retrospective cohort study, 
patients with T1G3 disease receiving early cystectomy had a better 10-year cancer-specific 
survival of 78% compared to 51% in those receiving deferred cystectomy (30). The BRAVO 
prospective randomized trial comparing radical cystectomy and BCG therapy in high-risk 
NMIBC was closed due to poor accrual (31, 32). In case of BCG shortage, upfront 
cystectomy should be discussed in case of high-risk NMIBC. 
 
CONCLUSION 
In conclusion, the severity and length of BCG shortages and the availability of alternative 
options will influence the choice of therapy in each country and hospital. Based on our 
review we recommend early liaison with the local pharmacist and BCG supplier to consider 
alternative BCG strains or sterile splitting of BCG doses. In the complete absence of BCG, 
consideration should be given, where available, to MMC or alternative intravesical 




• During times of BCG shortage, reducing the dose of BCG to one third can allow a 
maintenance BCG schedule to be given but will have logistical implications. 
• Dose reduction is preferable to an induction course of full dose BCG alone or 
reducing the number of instillations which should be avoided.  
• MMC is inferior to BCG maintenance in terms of recurrence rate, but better than 
BCG induction alone.  
• Intravesical chemotherapies such as Gemcitabine and Epirubicin should be used when  
both BCG and MMC are in short supply. 
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